Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04500574 · ClinicalTrials.gov registry record · Phase 1
Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension
A Phase 1 study, sponsored by Massachusetts Eye and Ear Infirmary.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04500574 is a Phase 1 study that was terminated before completion, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 1 participants.
The verdict
NCT04500574, a Phase 1 study, was terminated before completion, sponsored by Massachusetts Eye and Ear Infirmary.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this research study, we will assess the safety, tolerability, comfort, and feasibility of lowering intraocular pressure using a novel Contact Lens Drug Delivery System with latanoprost. Latanoprost is a well-studied medication and has been used to treat glaucoma for decades. Currently, latanoprost is FDA-approved to be administered to patients as eye drops, but using eye drops has challenges (having to remember to take the drop, getting the drop in the eye). This clinical trial is being done to determine the safety, tolerability, and effectiveness of using latanoprost to deliver latanoprost in a new way (through a drug-eluting contact lens). The study includes two phases. Phase A is intended to assess safety and tolerability and Phase B to assess safety and effectiveness.
Interventions
- DRUG Latanoprost eluting contact lens
- DRUG Topical Latanoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04500574
The ClinicalTrials.gov registry entry for NCT04500574 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Latanoprost eluting contact lens is the first listed.
NCT04500574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04500574 about?
NCT04500574 is a clinical study titled "Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension". In this research study, we will assess the safety, tolerability, comfort, and feasibility of lowering intraocular pressure using a novel Contact Lens Drug Delivery System with latanoprost. Latanoprost is a well-studied medication and has been used to treat glaucoma for decades. Currently, latanopros...
What is the current status of trial NCT04500574?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-04-03. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT04500574?
The interventions under investigation include: Latanoprost eluting contact lens (DRUG), Topical Latanoprost (DRUG).
Who is sponsoring clinical trial NCT04500574?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.